全文获取类型
收费全文 | 179800篇 |
免费 | 15002篇 |
国内免费 | 1276篇 |
专业分类
耳鼻咽喉 | 2314篇 |
儿科学 | 3404篇 |
妇产科学 | 5319篇 |
基础医学 | 24163篇 |
口腔科学 | 3465篇 |
临床医学 | 30069篇 |
内科学 | 32765篇 |
皮肤病学 | 4396篇 |
神经病学 | 12617篇 |
特种医学 | 8261篇 |
外科学 | 22837篇 |
综合类 | 2193篇 |
现状与发展 | 5篇 |
一般理论 | 81篇 |
预防医学 | 11333篇 |
眼科学 | 4324篇 |
药学 | 13699篇 |
中国医学 | 1598篇 |
肿瘤学 | 13235篇 |
出版年
2023年 | 1726篇 |
2022年 | 2820篇 |
2021年 | 5040篇 |
2020年 | 3030篇 |
2019年 | 3771篇 |
2018年 | 5427篇 |
2017年 | 4511篇 |
2016年 | 5521篇 |
2015年 | 7043篇 |
2014年 | 8341篇 |
2013年 | 10045篇 |
2012年 | 13043篇 |
2011年 | 12929篇 |
2010年 | 8254篇 |
2009年 | 7358篇 |
2008年 | 9878篇 |
2007年 | 9649篇 |
2006年 | 8919篇 |
2005年 | 8424篇 |
2004年 | 7523篇 |
2003年 | 6539篇 |
2002年 | 5669篇 |
2001年 | 4836篇 |
2000年 | 4291篇 |
1999年 | 3672篇 |
1998年 | 1875篇 |
1997年 | 1668篇 |
1996年 | 1578篇 |
1995年 | 1421篇 |
1994年 | 1152篇 |
1993年 | 968篇 |
1992年 | 1819篇 |
1991年 | 1804篇 |
1990年 | 1586篇 |
1989年 | 1416篇 |
1988年 | 1290篇 |
1987年 | 1156篇 |
1986年 | 1131篇 |
1985年 | 1023篇 |
1984年 | 746篇 |
1983年 | 660篇 |
1982年 | 480篇 |
1981年 | 465篇 |
1980年 | 388篇 |
1979年 | 595篇 |
1978年 | 464篇 |
1977年 | 452篇 |
1976年 | 407篇 |
1974年 | 389篇 |
1972年 | 393篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
21.
Chih-Wei Hsu Sheng-Yu Lee Yao-Hsu Yang Liang-Jen Wang 《The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)》2020,23(10):653
BackgroundGeneric antidepressants are approved on the market based on evidence of bioequivalence to their brand-name versions. We aimed to assess whether generic antidepressants exert equal effectiveness as their brand-name counterparts for treating patients with depressive disorders.MethodsIn a nationwide, population-based cohort in Taiwan from 1997 through 2013, patients with a diagnosis of a depressive disorder aged between 18 and 65 years who were new users of antidepressant drugs were classified into either the brand-name group or the generic group. All patients were followed up until medication discontinuation or the end of the study period. We assessed the risk for hospitalization as a primary outcome and augmentation therapy, daily dose, medication discontinuation, or switching to another antidepressant as secondary outcomes.ResultsA total of 277 651 brand-name users (35.8% male; mean age: 41.2 years) and 270 583 generic users (35.8% male; mean age: 41.0 years) were divided into 10 different antidepressant groups (fluoxetine, sertraline, paroxetine, escitalopram, citalopram, venlafaxine, mirtazapine, moclobemide, imipramine, and bupropion). We found that patients treated with the generic form of sertraline, paroxetine, escitalopram, venlafaxine, mirtazapine, and bupropion demonstrated significantly higher risks of psychiatric hospitalization (adjusted hazard ratios ranged from 1.20–2.34), compared to their brand-name counterparts. The differences between brand-name antidepressants and their generic counterparts in secondary outcomes varied across different drugs.ConclusionsCompared to most generic antidepressants, brand-name drugs exhibited more protective effects on psychiatric hospitalization for depressive patients. These findings could serve as an important reference for clinicians when encountering patients with depressive disorder. 相似文献
22.
A mixed‐method study of effects of a therapeutic play intervention for children on parental anxiety and parents' perceptions of the intervention 下载免费PDF全文
23.
24.
25.
26.
Factors predicting the development of pressure ulcers in an at‐risk population who receive standardized preventive care: secondary analyses of a multicentre randomised controlled trial 下载免费PDF全文
27.
28.
Marginal rate-based analyses are widely used for the analysis of recurrent events in clinical trials. In many areas of application, the events are not instantaneous but rather signal the onset of a symptomatic episode representing a recurrent infection, respiratory exacerbation, or bout of acute depression. In rate-based analyses, it is unclear how to best handle the time during which individuals are experiencing symptoms and hence are not at risk. We derive the limiting value of the Nelson-Aalen estimator and estimators of the regression coefficients under a semiparametric rate-based model in terms of an underlying two-state process. We investigate the impact of the distribution of the episode durations, heterogeneity, and dependence on the asymptotic and finite sample properties of standard estimators. We also consider the impact of these features on power in trials designed to test intervention effects on rate functions. An application to a trial of individuals with herpes simplex virus is given for illustration. 相似文献
29.